Exploring imeglimin efficacy; A case series from a tertiary care hospital

Abstract

Imeglimin, a tetrahydro triazine containing drug,  is  a novel therapeutic agent for the treatment of Type2 Diabetes Mellitus. Imeglimin has been demonstrated to improve three main pathogenetic components of T2DM: increased gluconeogenesis, inadequate glucose-induced insulin production in beta cells, and peripheral insulin resistance. This case series aimed to evaluate the efficacy and safety of imeglimin in a real-world clinical setting among patients with type 2 diabetes who had inadequate glycemic control with their current treatment regimen. The cases are collected from a tertiary healthcare centre in Kerala, South India. Insights gleaned from the case series indicate that imeglimin significantly improves glycemic control, enhances insulin sensitivity, and preserves beta-cell function in patients with type 2 diabetes